Antibody-drug conjugates or ADCs are a class of therapeutics that are designed to deliver potent small molecule drugs selectively to cells that express a specific target antigen while limiting systemic exposure to the drug.
This is accomplished by conjugating a potent drug onto an antibody-based therapeutic with a linker that is exquisitely stable in plasma. The development of an effective ADC requires optimizing a number of design elements and an extensive understanding of absorption, distribution, metabolism/catabolism, and elimination processes or ADME for the ADC construct. Furthermore, as ADCs are a combination of an antibody and small molecule drug, understanding key aspects of the ADME of each individual component is needed. In this article in Drug Metabolism and Disposition, published by The American Society for Pharmacology and Experimental Therapeutics, Tae Han abd Baiteng Zhao review considerations for the development of ADCs from an ADME point of view.
Published in: Drug Metabolism and Disposition